| |
| |
|
| Insider
Information: |
Sullivan Timothy Eugene |
| Relationship: |
|
| City: |
Research Triangle Park |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
79,174 |
|
|
Indirect Shares
|
70,396 |
|
|
| Direct
Value |
$3,475,739 |
|
|
|
Indirect Value
|
$3,090,384 |
|
|
| Total
Shares |
149,570 |
|
|
| Total
Value |
$6,566,123 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -113.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
|
2024-04-18 |
79,174 |
2024-04-18 |
70,396 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2024-04-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,164 |
70,396 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2024-04-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
14,164 |
79,174 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-04-01 |
4 |
AS |
$58.66 |
$234,640 |
D/D |
(4,000) |
93,338 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-04-01 |
4 |
OE |
$10.03 |
$40,120 |
D/D |
4,000 |
97,338 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-03-01 |
4 |
OE |
$10.03 |
$60,180 |
D/D |
6,000 |
99,338 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-03-01 |
4 |
AS |
$62.86 |
$379,340 |
D/D |
(6,000) |
93,338 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-02-12 |
4 |
S |
$67.77 |
$96,974 |
D/D |
(1,431) |
93,338 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-01-29 |
4 |
S |
$64.14 |
$58,109 |
D/D |
(906) |
94,769 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-01-22 |
4 |
S |
$65.00 |
$230,801 |
D/D |
(3,551) |
95,675 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
23,748 |
101,461 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2024-01-16 |
4 |
S |
$66.81 |
$149,317 |
D/D |
(2,235) |
99,226 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-11-30 |
4 |
AS |
$54.73 |
$774,884 |
D/D |
(14,158) |
77,713 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-11-30 |
4 |
OE |
$10.03 |
$142,005 |
D/D |
14,158 |
91,871 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-07-03 |
4 |
AS |
$89.41 |
$609,928 |
D/D |
(6,779) |
77,713 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-07-03 |
4 |
OE |
$10.03 |
$67,993 |
D/D |
6,779 |
84,492 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-06-05 |
4 |
AS |
$87.79 |
$6,196,527 |
D/D |
(69,779) |
77,713 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-06-05 |
4 |
OE |
$10.03 |
$699,883 |
D/D |
69,779 |
147,492 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2023-05-03 |
4 |
GA |
$0.00 |
$0 |
I/I |
20,000 |
56,232 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2023-05-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
77,713 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2023-04-19 |
4 |
GA |
$0.00 |
$0 |
I/I |
36,232 |
36,232 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2023-04-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
36,232 |
97,713 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2023-02-21 |
4 |
D |
$58.50 |
$56,979 |
D/D |
(974) |
133,945 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2023-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
11,683 |
134,919 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-02-10 |
4 |
D |
$51.21 |
$49,930 |
D/D |
(975) |
123,236 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Financial Officer |
• • – |
2023-01-27 |
4 |
D |
$52.77 |
$29,076 |
D/D |
(551) |
124,211 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
